CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma

Author(s):
Karkampouna, S.; Helm, D. van der; Gray, P.C.; Chen, L.P.; Klima, I.; Grosjean, J.; Burgmans, M.C.; Farina-Sarasqueta, A.; Snaar-Jagalska, E.B.; Stroka, D.M.; Terracciano, L.; Hoek, B. van (0000-0001-6527-764X); Schaapherder, A.F.; Osanto, S.; Thalmann, G.N.; Verspaget, H.W. (0000-0001-5769-6887); Coenraad, M.J.; Kruithof-de Julio, M.
Published
2018
Publication type
Article / Letter to editor
hepatocellular carcinomaCRIPTOGRP78HepG2sorafenib resistanceorganoidsliver cirrhosisneoplasiapatient-derived xenograftszebrafish xenograft
Date issued
2018-07-31
Language
English
Is part of
Journal of Pathology (2018), Vol. 245, no. 3, p. 297-310
hdl
1887/75152
doi
10.1002/path.5083